Eine Studie zur Bewertung der Wirksamkeit und Sicherheit von Bimekizumab bei Studienteilnehmern mit mittelschwerer bis schwerer Hidradenitis suppurativa (BE HEARD I)
Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit von Bimekizumab bei Studienteilnehmern mit mittelschwerer bis schwerer Hidradenitis suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Campbelltown, Australien
- Hs0003 30015
-
Carlton, Australien
- Hs0003 30016
-
East Melbourne, Australien
- Hs0003 30011
-
Kogarah, Australien
- Hs0003 30017
-
Woolloongabba, Australien
- Hs0003 30012
-
-
-
-
-
Brussels, Belgien
- Hs0003 40004
-
Brussels, Belgien
- Hs0003 40121
-
Leuven, Belgien
- Hs0003 40002
-
Liège, Belgien
- Hs0003 40060
-
-
-
-
-
Berlin, Deutschland
- Hs0003 40325
-
Bochum, Deutschland
- Hs0003 40248
-
Bonn, Deutschland
- Hs0003 40327
-
Darmstadt, Deutschland
- Hs0003 40288
-
Dresden, Deutschland
- Hs0003 40324
-
Kiel, Deutschland
- Hs0003 40249
-
Magdeburg, Deutschland
- Hs0003 40357
-
Mainz, Deutschland
- Hs0003 40174
-
München, Deutschland
- Hs0003 40323
-
Münster, Deutschland
- Hs0003 40177
-
-
-
-
-
Aarhus N, Dänemark
- Hs0003 40127
-
-
-
-
-
Amiens, Frankreich
- Hs0003 40197
-
Angers, Frankreich
- Hs0003 40342
-
Le Mans, Frankreich
- Hs0003 40355
-
Nice, Frankreich
- Hs0003 40132
-
Rouen, Frankreich
- Hs0003 40318
-
Saint-Mandé, Frankreich
- Hs0003 40246
-
Toulon, Frankreich
- Hs0003 40285
-
-
-
-
-
Athens, Griechenland
- Hs0003 40251
-
Athens, Griechenland
- Hs0003 40253
-
Thessaloniki, Griechenland
- Hs0003 40252
-
-
-
-
-
Haifa, Israel
- Hs0003 20089
-
Tel Aviv, Israel
- Hs0003 20088
-
-
-
-
-
Catania, Italien
- Hs0003 40261
-
Roma, Italien
- Hs0003 40257
-
Roma, Italien
- Hs0003 40263
-
Rozzano, Italien
- Hs0003 40258
-
Terracina, Italien
- Hs0003 40331
-
Torino, Italien
- Hs0003 40330
-
-
-
-
-
Barrie, Kanada
- Hs0003 50233
-
Richmond Hill, Kanada
- Hs0003 50190
-
Saskatoon, Kanada
- Hs0003 50192
-
St. John's, Kanada
- Hs0003 50173
-
Surrey, Kanada
- Hs0003 50133
-
-
-
-
-
Breda, Niederlande
- Hs0003 40351
-
Groningen, Niederlande
- Hs0003 40292
-
Rotterdam, Niederlande
- Hs0003 40264
-
-
-
-
-
Trondheim, Norwegen
- Hs0003 40332
-
-
-
-
-
Bern, Schweiz
- Hs0003 40337
-
Geneva, Schweiz
- Hs0003 40406
-
-
-
-
-
Badalona, Spanien
- Hs0003 40266
-
Las Palmas de Gran Canaria, Spanien
- Hs0003 40294
-
Pontevedra, Spanien
- Hs0003 40295
-
Seville, Spanien
- Hs0003 40049
-
Valencia, Spanien
- Hs0003 40230
-
-
-
-
-
Ankara, Türkei (türkiye)
- Hs0003 40053
-
Antalya, Türkei (türkiye)
- Hs0003 40270
-
Gaziantep, Türkei (türkiye)
- Hs0003 40273
-
Istanbul, Türkei (türkiye)
- Hs0003 40050
-
Istanbul, Türkei (türkiye)
- Hs0003 40272
-
Izmir, Türkei (türkiye)
- Hs0003 40271
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Hs0003 50140
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85006
- Hs0003 50175
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90045
- Hs0003 50161
-
San Diego, California, Vereinigte Staaten, 92123
- Hs0003 50220
-
-
Florida
-
North Miami Beach, Florida, Vereinigte Staaten, 33162-4708
- Hs0003 50205
-
Ormond Beach, Florida, Vereinigte Staaten, 32174
- Hs0003 50153
-
Tampa, Florida, Vereinigte Staaten, 33613
- Hs0003 50141
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30309
- Hs0003 50210
-
Watkinsville, Georgia, Vereinigte Staaten, 30677
- Hs0003 50280
-
-
Kentucky
-
Murray, Kentucky, Vereinigte Staaten, 42071
- Hs0003 50425
-
-
Massachusetts
-
Beverly, Massachusetts, Vereinigte Staaten, 01915
- Hs0003 50198
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Hs0003 50146
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68144
- Hs0003 50194
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89148
- Hs0003 50208
-
-
New Jersey
-
East Windsor, New Jersey, Vereinigte Staaten, 08520
- Hs0003 50137
-
-
New York
-
New York, New York, Vereinigte Staaten, 10003
- Hs0003 50235
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27516
- Hs0003 50151
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- Hs0003 50177
-
Columbus, Ohio, Vereinigte Staaten, 43213
- Hs0003 50138
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74135
- Hs0003 50204
-
-
Pennsylvania
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033
- Hs0003 50147
-
-
Rhode Island
-
Johnston, Rhode Island, Vereinigte Staaten, 02919
- Hs0003 50008
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Hs0003 50180
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37215
- Hs0003 50142
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten, 76011
- Hs0003 50201
-
Dallas, Texas, Vereinigte Staaten, 75246
- Hs0003 50166
-
San Antonio, Texas, Vereinigte Staaten, 78213
- Hs0003 50149
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98101
- Hs0003 50270
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent and is at least 18 years of age, written informed consent will be obtained from both the study participant and the legal representative
-
Study participants must have a diagnosis of Hidradenitis Suppurativa (HS) based on clinical history and physical examination for at least 6 months prior to the Baseline visit
-
Study participant must have HS lesions present in at least 2 distinct anatomic areas (eg, left and right axilla), 1 of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits
-
Study participant must have moderate to severe HS defined as a total of ≥5 inflammatory lesions (ie, number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits
-
Study participant must have had an inadequate response to a course of a systemic antibiotic for treatment of HS as assessed by the Investigator through study participant interview and review of medical history
-
A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) OR
- A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 20 weeks after the last dose of investigational medicinal product (IMP)
Exclusion Criteria:
- Draining tunnel count of >20 at the Baseline Visit
- Any other active skin disease or condition (eg, bacterial cellulitis, candida intertrigo, extensive condyloma) that may, in the opinion of the Investigator, interfere with the assessment of hidradenitis suppurativa (HS)
- Study participant has a diagnosis of sarcoidosis, systemic lupus erythematosus, or active inflammatory bowel disease (IBD)
- Primary immunosuppressive condition, including taking immunosuppressive therapy following an organ transplant, or has had a splenectomy
- Female who is breastfeeding, pregnant, or plans to become pregnant during the study or within 20 weeks following the final dose of investigational medicinal product (IMP)
- Active infection or history of certain infection(s)
- Active tuberculosis (TB) infection, latent TB infection, high risk of exposure to TB infection, current or history of nontuberculous mycobacterium (NTM) infection
- Concurrent malignancy. Study participants with a history of malignancy within the past 5 years prior to the Screening Visit are excluded, EXCEPT if the malignancy was a cutaneous squamous or basal cell carcinoma, or in situ cervical cancer that has been treated and is considered cured
- History of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease
- Known hypersensitivity to any components of bimekizumab or comparative drugs as stated in this protocol
- Concomitant and prior medication restrictions
- Myocardial infarction or stroke within the 6 months prior to the Screening Visit
- Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
- Presence of moderately severe major depression or severe major depression
- Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Bimekizumab dosing regimen 1
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andere Namen:
|
|
Experimental: Bimekizumab dosing regimen 2
Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andere Namen:
|
|
Experimental: Bimekizumab dosing regimen 3
Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andere Namen:
|
|
Placebo-Komparator: Placebo Group
Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period. |
Subjects will receive bimekizumab at pre-specified time-points.
Andere Namen:
Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16
Zeitfenster: Week 16
|
HiSCR50 was defined as at least a 50 percent (%) reduction from Baseline in the total abscess and inflammatory nodule (AN) count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data are imputed using multiple imputation with Markov Chain Monte Carlo (MCMC) method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an adverse event (AE) or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model. |
Week 16
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
Zeitfenster: Week 16
|
HiSCR75 was defined as at least a 75% reduction from Baseline in the total AN count, with no increase from Baseline in abscess or draining tunnel count. Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Lesion counts were imputed and then dichotomized to obtain the response status. Participants who experienced an intercurrent event were treated as nonresponders following the intercurrent event. An intercurrent event was defined as receipt of systemic antibiotic rescue medication or discontinuation of study treatment due to an AE or lack of efficacy. Percentage of participants shown do not account for model effects using the logistic regression model. |
Week 16
|
|
Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 16
Zeitfenster: Baseline, Week 16
|
The DLQI is a patient-reported questionnaire designed for use in adult participants with skin diseases and Hidradenitis Suppurativa (HS). The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect patients' health related quality of life (HRQoL), with a recall period of 7 days. This instrument asks participants 10 questions about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The scoring of each answer for the DLQI is on a scale range of 0 (not at all) to 3 (very much). The DLQI total score was calculated by adding the score of each question. The maximum score is 30, and the minimum score is 0. The higher the score, the more quality of life is impaired. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. |
Baseline, Week 16
|
|
Absolute Change From Baseline in Worst Skin Pain Score at Week 16
Zeitfenster: Baseline, Week 16
|
Absolute change from Baseline in Worst Skin Pain score at Week 16 was assessed using the worst skin pain item in the Hidradenitis Suppurativa Symptom Daily Diary (HSSDD). Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The worst skin pain score was derived from the weekly average of daily scores, defined as the sum of the scored item over the course of the study week divided by the number of days in which the item was completed, relative to each respective visit date. Intermittent missing data are imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Participants who experienced an intercurrent event were treated as missing following the intercurrent event and imputed using the multiple imputation method for missing data. Mean values shown do not account for model effects using the ANCOVA model. |
Baseline, Week 16
|
|
Percentage of Participants Achieving Worst Skin Pain Response at Week 16
Zeitfenster: Week 16
|
Skin pain response at Week 16, as assessed by "worst skin pain" item in HSSDD, was defined as an improvement in weekly worst skin pain score of at least 3 points versus Baseline. Worst skin pain during the past 24 hours was assessed daily using an 11-point numeric rating scale (NRS) which ranges from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). Worst skin pain score was derived from weekly average of daily scores (sum of scored item over study week/number of days in which item completed, relative to each respective visit). Intermittent missing data were imputed using multiple imputation with MCMC method followed by monotone regression for monotone missing data. Weekly pain scores were imputed and then dichotomized to obtain response status. Participants who experienced an intercurrent event were treated as non-responders following the intercurrent event. Percentage of participants shown do not account for model effects using logistic regression model. |
Week 16
|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study
Zeitfenster: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety Follow-Up [SFU] period). |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
|
Percentage of Participants With Serious Treatment-emergent Adverse Events During the Study
Zeitfenster: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death; Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical events. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
Zeitfenster: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs are defined as AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). TEAEs leading to discontinuation of the study are reported. |
From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: UCB Cares, 001 844 599 2273
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I, Muller E, Pelligra CG, Ingram JR. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL(c)) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. Br J Dermatol. 2025 Jun 20;193(1):93-104. doi: 10.1093/bjd/ljaf067.
- Ingram JR, Lambert J, Ciaravino V, Rolleri R, Pansar I, Peterson L, Pelligra CG, Thorlacius L. Hidradenitis Suppurativa Symptom Daily Diary (HSSDD) and Questionnaire (HSSQ): Psychometric Validation and Interpretation Threshold Derivation Using Phase 3 Study Data. Dermatol Ther (Heidelb). 2025 May;15(5):1093-1111. doi: 10.1007/s13555-025-01346-w. Epub 2025 Mar 28.
- Shi VY, Ingram JR, Lev-Tov H, Schneider-Burrus S, Forman S, Porter ML, Hayama K, Thorlacius L, Lambert J, Vaux T, Lukowski B, Rolleri RL, Szepietowski JC. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Dermatol Ther (Heidelb). 2025 Sep;15(9):2553-2570. doi: 10.1007/s13555-025-01465-4. Epub 2025 Jul 13.
- Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024 Jun 8;403(10443):2504-2519. doi: 10.1016/S0140-6736(24)00101-6. Epub 2024 May 22.
- Ingram JR, Fujita H, Gottlieb AB, Lev-Tov H, Prens E, Sayed CJ, Shi VY, Szepietowski JC, Takahashi K, Frew JW, Lambert J, Davis L, Oh T, Rolleri R, Saintmard MH, Orenstein LAV. Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials. Pain Ther. 2025 Dec;14(6):1861-1878. doi: 10.1007/s40122-025-00779-7. Epub 2025 Oct 17.
- Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC. Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II. J Eur Acad Dermatol Venereol. 2026 Feb 14. doi: 10.1111/jdv.70356. Online ahead of print.
- Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG. Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension. J Am Acad Dermatol. 2026 Mar;94(3):867-878. doi: 10.1016/j.jaad.2025.11.031. Epub 2025 Nov 15.
- Aleshin MA, Tran T, Pansar I, Shang A, Friesen D, Kimball AB. Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA. Drugs Real World Outcomes. 2026 Jul 29. doi: 10.1007/s40801-026-00564-8. Online ahead of print.
- Chovatiya R, Alavi A, Miyagawa T, Turchin I, Tzellos T, van der Zee HH, Crater C, Lukowski B, Tilt N, Zouboulis CC. Bimekizumab 2-year efficacy by hidradenitis suppurativa duration: BE HEARD EXT results. J Eur Acad Dermatol Venereol. 2026 Jul 22. doi: 10.1111/jdv.70631. Online ahead of print. No abstract available.
- Daveluy S, Gottlieb AB, Augustin M, Lev-Tov H, Szepietowski JC, Horvath B, Porter ML, Hayama K, Lambert J, Tilt N, Lukowski B, Thorlacius L. Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II. Dermatol Ther (Heidelb). 2026 Jul;16(7):3315-3329. doi: 10.1007/s13555-026-01790-2. Epub 2026 Jun 5.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- HS0003
- 2019-002550-23 (EudraCT-Nummer)
- 2019 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD-Sharing-Zeitrahmen
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD-Sharing-Zugriffskriterien
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .